Jazz Pharmaceuticals Director Patrick Enright Receives RSU Award

What Happened Patrick G. Enright, a director of Jazz Pharmaceuticals plc (JAZZ), received a grant of 1,605 restricted stock units (RSUs) on August 5, 2026. The units were awarded at a $0.00 per-unit price (no cash paid); the reported aggregate value is $0 because RSUs are contingent awards rather than open-market purchases.

Key Details

• Transaction date: 2026-08-05; Form 4 filed: 2026-08-07 (timely filing).
• Transaction type/code: Award/Grant (A).
• Amount: 1,605 RSUs granted; reported price $0.00, aggregate $0.
• Shares owned after transaction: not specified in the filing.
• Footnote: RSUs granted under the Issuer's 2007 Amended and Restated Non‑Employee Directors Stock Award Plan. Each RSU represents a contingent right to one ordinary share. Subject to continuous service and other conditions, the units vest in full on July 23, 2027 (see footnote F1).

Context RSUs are compensation awards that convert to ordinary shares upon vesting and do not reflect an immediate cash purchase or sale by the insider. Such grants are common for non-employee directors as part of board compensation and should be interpreted as a compensation event rather than a direct market sentiment signal.